Viral Vector-Based Gene Therapy Global Market Report 2025

Description

Viral vector based gene therapy is a medical approach that employs engineered viruses to deliver therapeutic genes into a patient's cells to treat or prevent diseases. The viral vectors are modified to be safe and replication deficient while efficiently transferring genetic material to target cells. This therapy allows correction of genetic defects, modulation of gene expression, or stimulation of immune responses to achieve long lasting therapeutic effects.

The main vector types of viral vector based gene therapy include adenoviral vectors, adeno associated viral vectors, lentiviral vectors, retroviral vectors, and others. Adenoviral vectors are engineered viruses derived from adenoviruses that are modified to safely deliver therapeutic genes into target cells without replication and are commonly used in gene therapy and vaccine applications. They are administered through various routes, including intravenous injection, intrathecal injection, intramuscular injection, subcutaneous injection, and topical application. They are applied in oncology, genetic disorders, cardiovascular diseases, infectious diseases, neurological disorders, and others, serving end users such as hospitals, clinical research organizations (CROs), academic and research institutes, pharmaceutical and biotechnology companies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The viral vector-based gene therapy market research report is one of a series of new reports from The Business Research Company that provides viral vector-based gene therapy market statistics, including the viral vector-based gene therapy industry global market size, regional shares, competitors with the viral vector-based gene therapy market share, detailed viral vector-based gene therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the viral vector-based gene therapy industry. This viral vector-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The viral vector-based gene therapy market size has grown rapidly in recent years. It will grow from $5.77 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to rising funding for gene therapy research, growing biopharmaceutical manufacturing capacity, increasing mergers and acquisitions in the gene therapy sector, expansion of viral vector production facilities, and rising government support for advanced therapy development.

The viral vector-based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $12.68 billion in 2029 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to rising investment in large scale vector manufacturing, increasing focus on commercial gene therapy production, growing adoption of automation in vector processing, expansion of global biomanufacturing infrastructure, and rising collaboration between biotech and contract development and manufacturing organization (CDMO) companies. Major trends in the forecast period include technological advancements in vector design, innovations in delivery methods, developments in large scale manufacturing, research and development in next generation vectors, and improvements in safety and efficacy profiles.

The increasing prevalence of genetic diseases is expected to drive the growth of the viral vector-based gene therapy market in the coming years. Genetic diseases are disorders caused by DNA changes or mutations, which can be inherited or occur spontaneously, affecting health, development, or bodily functions. The rising prevalence is driven by increased awareness and advancements in diagnostic technologies, which allow earlier and more accurate detection of conditions that previously went undiagnosed. Viral vector-based gene therapy supports genetic disease management by enabling targeted delivery of therapeutic genes, making it suitable for treating inherited disorders. It slows disease progression by providing precise and long-lasting correction of genetic defects, improving patient outcomes and quality of life. For example, in April 2025, according to the International Diabetes Federation, a Belgium based non-profit organization, approximately 589 million people were living with diabetes in 2024, and this number is projected to increase to 853 million by 2050. Therefore, the growing prevalence of genetic diseases is driving the expansion of the viral vector-based gene therapy market.

Major companies in the viral vector-based gene therapy market are developing advanced platforms such as integrated manufacturing platforms to improve efficiency, enhance reliability, and reduce production cost and time. Integrated manufacturing platforms are comprehensive systems that streamline the entire production process for gene therapies, from vector design to final product, using standardized high-yield procedures. For example, in October 2024, Forge Biologics Holdings LLC, a US based biotechnology company, launched the FUEL AAV Manufacturing Platform. This proprietary, suspension-based system is designed for high productivity and scalability. It includes a fully integrated plasmid system and optimized processes, enabling robust and consistent production of adeno-associated viral (AAV) vectors for gene therapies, thereby accelerating development timelines from research to clinical trials.

In July 2023, Sartorius AG, a Germany based company providing laboratory and biopharmaceutical equipment and services, acquired Polyplus SAS for an undisclosed amount. Through this acquisition, Sartorius aims to strengthen its capabilities in supplying critical transfection reagents and related technologies for efficient viral vector production in gene and gene-modified cell therapies. Polyplus SAS is a France based company that provides upstream technologies, products, and services for the manufacturing of viral vectors used in gene therapies.

Major companies operating in the viral vector-based gene therapy market are F. Hoffmann-La Roche AG, Novartis AG, Fujifilm Holdings Corporation, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., PTC Therapeutics Inc., 4D Molecular Therapeutics Inc., Editas Medicine Inc., Regenxbio Inc., Oxford Biomedica plc, MeiraGTx Holdings plc, Voyager Therapeutics Inc., Solid Biosciences Inc., Sangamo Therapeutics Inc., Adverum Biotechnologies Inc., Passage Bio Inc., Dyno Therapeutics Inc., Genethon, uniQure N.V., Spur Therapeutics Inc.

North America was the largest region in the viral vector-based gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in viral vector-based gene therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the viral vector-based gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The viral vector-based gene therapy market includes revenues earned by entities through process development, vector design, cell line development, assay development, process optimization, manufacturing, upstream production, and downstream purification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Vector-Based Gene Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral vector-based gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral vector-based gene therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The viral vector-based gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Vector Type: Adenoviral Vectors; Adeno-Associated Viral Vectors; Lentiviral Vectors; Retroviral Vectors; Other Viral Vectors
2) By Delivery Method: Intravenous Injection; Intrathecal Injection; Intramuscular Injection; Subcutaneous Injection; Topical Application
3) By Application: Oncology; Genetic Disorders; Cardiovascular Diseases; Infectious Diseases; Neurological Disorders; Other Applications
4) By End User: Hospitals; Clinical Research Organizations (CROs); Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
Subsegments:
1) By Adenoviral Vectors: Human Adenovirus Serotype Five; Human Adenovirus Serotype Two; Canine Adenovirus; Other Adenoviruses
2) By Adeno-Associated Viral Vectors: Adeno-Associated Virus Serotype One; Adeno-Associated Virus Serotype Two; Adeno-Associated Virus Serotype Five; Adeno-Associated Virus Serotype Eight; Other Adeno-Associated Viruses
3) By Lentiviral Vectors: Human Immunodeficiency Virus One; Human Immunodeficiency Virus Two; Other Lentiviruses
4) By Retroviral Vectors: Gammaretrovirus; Alpharetrovirus; Spumaretrovirus; Other Retroviruses
Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Fujifilm Holdings Corporation; BioMarin Pharmaceutical Inc.; Sarepta Therapeutics Inc.; Ultragenyx Inc.; Krystal Biotech Inc.; Rocket Pharmaceuticals Inc.; PTC Therapeutics Inc.; 4D Molecular Therapeutics Inc.; Editas Medicine Inc.; Regenxbio Inc.; Oxford Biomedica plc; MeiraGTx Holdings plc; Voyager Therapeutics Inc.; Solid Biosciences Inc.; Sangamo Therapeutics Inc.; Adverum Biotechnologies Inc.; Passage Bio Inc.; Dyno Therapeutics Inc.; Genethon; uniQure N.V.; Spur Therapeutics Inc.
Countries:

Product Code: r40163

1. Executive Summary

2. Viral Vector-Based Gene Therapy Market Characteristics

3. Viral Vector-Based Gene Therapy Market Trends And Strategies

4. Viral Vector-Based Gene Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Viral Vector-Based Gene Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Viral Vector-Based Gene Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Viral Vector-Based Gene Therapy Market Growth Rate Analysis
5.4. Global Viral Vector-Based Gene Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Viral Vector-Based Gene Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Viral Vector-Based Gene Therapy Total Addressable Market (TAM)

6. Viral Vector-Based Gene Therapy Market Segmentation

6.1. Global Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenoviral Vectors
Adeno-Associated Viral (AAV) Vectors
Lentiviral Vectors
Retroviral Vectors
Other Viral Vectors
6.2. Global Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous Injection
Intrathecal Injection
Intramuscular Injection
Subcutaneous Injection
Topical Application
6.3. Global Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Genetic Disorders
Cardiovascular Diseases
Infectious Diseases
Neurological Disorders
Other Applications
6.4. Global Viral Vector-Based Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinical Research Organizations (CROs)
Academic And Research Institutes
Pharmaceutical And Biotechnology Companies
Other End Users
6.5. Global Viral Vector-Based Gene Therapy Market, Sub-Segmentation Of Adenoviral Vectors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human Adenovirus Serotype Five
Human Adenovirus Serotype Two
Canine Adenovirus
Other Adenoviruses
6.6. Global Viral Vector-Based Gene Therapy Market, Sub-Segmentation Of Adeno-Associated Viral Vectors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adeno-Associated Virus Serotype One
Adeno-Associated Virus Serotype Two
Adeno-Associated Virus Serotype Five
Adeno-Associated Virus Serotype Eight
Other Adeno-Associated Viruses
6.7. Global Viral Vector-Based Gene Therapy Market, Sub-Segmentation Of Lentiviral Vectors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human Immunodeficiency Virus One
Human Immunodeficiency Virus Two
Other Lentiviruses
6.8. Global Viral Vector-Based Gene Therapy Market, Sub-Segmentation Of Retroviral Vectors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gammaretrovirus
Alpharetrovirus
Spumaretrovirus
Other Retroviruses

7. Viral Vector-Based Gene Therapy Market Regional And Country Analysis

7.1. Global Viral Vector-Based Gene Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Viral Vector-Based Gene Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral Vector-Based Gene Therapy Market

8.1. Asia-Pacific Viral Vector-Based Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral Vector-Based Gene Therapy Market

9.1. China Viral Vector-Based Gene Therapy Market Overview
9.2. China Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral Vector-Based Gene Therapy Market

10.1. India Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral Vector-Based Gene Therapy Market

11.1. Japan Viral Vector-Based Gene Therapy Market Overview
11.2. Japan Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral Vector-Based Gene Therapy Market

12.1. Australia Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral Vector-Based Gene Therapy Market

13.1. Indonesia Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral Vector-Based Gene Therapy Market

14.1. South Korea Viral Vector-Based Gene Therapy Market Overview
14.2. South Korea Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral Vector-Based Gene Therapy Market

15.1. Western Europe Viral Vector-Based Gene Therapy Market Overview
15.2. Western Europe Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral Vector-Based Gene Therapy Market

16.1. UK Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral Vector-Based Gene Therapy Market

17.1. Germany Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral Vector-Based Gene Therapy Market

18.1. France Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral Vector-Based Gene Therapy Market

19.1. Italy Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral Vector-Based Gene Therapy Market

20.1. Spain Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral Vector-Based Gene Therapy Market

21.1. Eastern Europe Viral Vector-Based Gene Therapy Market Overview
21.2. Eastern Europe Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral Vector-Based Gene Therapy Market

22.1. Russia Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral Vector-Based Gene Therapy Market

23.1. North America Viral Vector-Based Gene Therapy Market Overview
23.2. North America Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral Vector-Based Gene Therapy Market

24.1. USA Viral Vector-Based Gene Therapy Market Overview
24.2. USA Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral Vector-Based Gene Therapy Market

25.1. Canada Viral Vector-Based Gene Therapy Market Overview
25.2. Canada Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral Vector-Based Gene Therapy Market

26.1. South America Viral Vector-Based Gene Therapy Market Overview
26.2. South America Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral Vector-Based Gene Therapy Market

27.1. Brazil Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral Vector-Based Gene Therapy Market

28.1. Middle East Viral Vector-Based Gene Therapy Market Overview
28.2. Middle East Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral Vector-Based Gene Therapy Market

29.1. Africa Viral Vector-Based Gene Therapy Market Overview
29.2. Africa Viral Vector-Based Gene Therapy Market, Segmentation By Vector Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Viral Vector-Based Gene Therapy Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Viral Vector-Based Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral Vector-Based Gene Therapy Market Competitive Landscape And Company Profiles

30.1. Viral Vector-Based Gene Therapy Market Competitive Landscape
30.2. Viral Vector-Based Gene Therapy Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Viral Vector-Based Gene Therapy Market Other Major And Innovative Companies

31.1. Ultragenyx Inc.
31.2. Krystal Biotech Inc.
31.3. Rocket Pharmaceuticals Inc.
31.4. PTC Therapeutics Inc.
31.5. 4D Molecular Therapeutics Inc.
31.6. Editas Medicine Inc.
31.7. Regenxbio Inc.
31.8. Oxford Biomedica plc
31.9. MeiraGTx Holdings plc
31.10. Voyager Therapeutics Inc.
31.11. Solid Biosciences Inc.
31.12. Sangamo Therapeutics Inc.
31.13. Adverum Biotechnologies Inc.
31.14. Passage Bio Inc.
31.15. Dyno Therapeutics Inc.

32. Global Viral Vector-Based Gene Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral Vector-Based Gene Therapy Market

34. Recent Developments In The Viral Vector-Based Gene Therapy Market

35. Viral Vector-Based Gene Therapy Market High Potential Countries, Segments and Strategies

35.1 Viral Vector-Based Gene Therapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Viral Vector-Based Gene Therapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Viral Vector-Based Gene Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer